Scientists develop targeted therapy for T-cell lymphomas and leukemias

Researchers at the Johns Hopkins Kimmel Cancer Center’s Ludwig Center developed a new treatment that selectively targets TRBC2-positive T-cell cancers, expanding a precision approach they established in 2024 for TRBC1-positive tumors.

Continue Reading

News Source: medicalxpress.com